FDA Approves Pfizer’s Biosimilar of Neupogen® as Amgen and Pfizer Litigate Patent Infringement

Not all biosimilar applicants initiate the patent dance, however. … Circuit held that the BPCIA’s requirement also is not enforceable under state law.